DigestRedComo funciona
Red
/
Empresas
Im
No verificado

ImmunityBio, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

75 Comunicados de prensa

Ver todos los comunicados de prensa
01/06/2026
Eventos
Ferias y Congresos
Industria
Farmacéutica
Salud
Oncología
Medicina - Varios
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
22/05/2026
Eventos
Industria
Análisis de Mercados
Asociaciones/Profesionales
Biotecnología
Farmacéutica
Oncología
Salud
VIH, SIDA y enfermedades autoinmunes
Sanidad
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
22/05/2026
Farmacéutica
Salud
Oncología
Medicina - Varios
Eventos
Industria
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
20/05/2026
Ciencia
Biotecnología
Farmacéutica
Oncología
Salud
Higiene alimentaria
Medicina - Varios
Industria
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
19/05/2026
Industria
Ciencia
Medicina - Varios
Sanidad
Biotecnología
Farmacéutica
Salud
Oncología
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
18/05/2026
Biotecnología
VIH, SIDA y enfermedades autoinmunes
Salud
Farmacéutica
Oncología
Industria
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
16/05/2026
Ciencia
Higiene alimentaria
Medicina - Varios
Biotecnología
Salud
Farmacéutica
Sanidad
Oncología
Web y redes sociales
Mercado laboral
Eventos
Industria
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
07/05/2026
Mercado de valores
Biotecnología
Salud
Sanidad
Farmacéutica
Oncología
Material médico sanitario
Ciencia
VIH, SIDA y enfermedades autoinmunes
Medicina - Varios
ImmunityBio Reports Record Q1 2026 Results: Net Product Revenue Increased Nearly 2.7x Year-Over-Year to $44 Million in Q1 2026 Expanding on the 2025 Full Year 700% Year-Over-Year Revenue Growth; Cash and Marketable Securities Total $381 Million
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
05/05/2026
Eventos
Ferias y Congresos
Industria
Oncología
Salud
Medicina - Varios
Ciencia
Farmacéutica
Biotecnología
ImmunityBio to Present New Comparative Data, Scientific Advances in Non-Muscle Invasive Bladder Cancer CIS and an Update on BCG Naïve Registrational Trial at American Urological Association Annual Meeting
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0
21/04/2026
Mercado laboral
Industria
Biotecnología
Farmacéutica
Salud
Oncología
ImmunityBio Announces ANKTIVA® Is Now Available in Saudi Arabia for Bladder and Lung Cancer Patients; Market Entry Achieved Within Two Months of MENA Partnership
Fuente
ImmunityBio, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0